News
Market and company headlines
IVVDAll
Loading
03:00Oct 211 Story
03:00-08:00Oct 142 Stories
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
FLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination Syndrome, also known as COVID vaccine injuryDesign includes VYD2311 administered in three doses to assess the safety and potential clinical benefit of VYD2311 treatment versus placebo over 90 daysVYD2311 has demonstrated high in vitro antiviral potency across all SARS-CoV-2 variants
Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome
The Phase 2 FLINTLOCK clinical trial includes the following study features:Randomized, double-blind, placebo-controlled, proof-of-concept studyTests Invivyd’s monoclonal antibody VYD2311, an investigational monoclonal
07:00Oct 51 Story
22:00Oct 41 Story
12:00Sep 301 Story
08:00-11:00Sep 292 Stories
Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission
Invivyd reported statistically significant Phase 3 safety and tolerability results for VYD2311 compared with an mRNA-based COVID-19 vaccine and said it plans to pursue an Accelerated Approval BLA pending supportive results from its ongoing DECLARATION study. Key Investor TakeawaysInvivyd (NASDAQ:IVVD) said VYD2311 showed significantly lower rates of short-term overall adverse events and systemic adverse events than the mRNA COVID-19 vaccine in the Phase 3 LIBERTY study.
Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript
Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission September 29, 2026 8:30 AM EDTCompany...
06:00-08:00Sep 292 Stories
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and tolerability of an mRNA-based COVID-19 vaccineVYD2311 combined with an mRNA-based COVID-19 vaccine demonstrated no interference with vaccine-induced neutralizing titers, and instead added substantially to vaccine-induced neutralizing titersVYD2311 observed profile in LIBERTY indicates hig
Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission - Slideshow
2026-09-29. The following slide deck was published by Invivyd, Inc.
09:00Sep 211 Story
04:00Sep 141 Story
10:00Sep 131 Story
07:00Sep 81 Story
04:00-09:00Sep 12 Stories
These stocks are moving in today's pre-market session
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. Lakewood-Amedex (NASDAQ:LABT)
03:00Sep 12 Stories
Invivyd Continues To Expect Top-Line Data From VYD2311 Program Around The End Of Q3 2026
Invivyd continues to expect top-line data from the VYD2311 program around the end of Q3 2026. At that time, Invivyd plans to either unblind the DECLARATION study in its entirety and submit a Biologics License
Invivyd Appoints Marc Elia As CEO
Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategyAjay Royan, Founder of Mithril Capital and a founding, long-term investor in